Publications
View AllAdjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free surviv...
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- ES
- Publications
- 2
- Citations
- 4,436
External Links
Identifiers
- ROR
- https://ror.org/05b9vxh94